EcoDrugPlus

Atr Serine/threonine Kinase

Ensembl ID : ENSDARG00000079625
Gene Symbol: ATR
25 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSDARG00000112045
Gene Symbol: AXL
6 Cross references
188 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSDARG00000017661
Gene Symbol: BRAF
27 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator A

Ensembl ID : ENSDARG00000094704
Gene Symbol: BCL2A
5 Cross references
146 Possible Orthologues:

Bcl2 Apoptosis Regulator B

Ensembl ID : ENSDARG00000089109
Gene Symbol: BCL2B
11 Enzyme and pathways 5 Cross references
172 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSDARG00000008434
Gene Symbol: BCL2L1
9 Enzyme and pathways 5 Cross references
229 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSDARG00000026766
Gene Symbol: BCL2L10
5 Cross references
129 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSDARG00000042329
Gene Symbol: BCR
6 Cross references
203 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSDARG00000079286
Gene Symbol: BCR
3 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Bruton Agammaglobulinemia Tyrosine Kinase

Ensembl ID : ENSDARG00000004433
Gene Symbol: BTK
21 Enzyme and pathways 5 Cross references
204 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSDARG00000041107
Gene Symbol: CFTR
17 Enzyme and pathways 5 Cross references
217 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSDARG00000030756
Gene Symbol: DNMT1
8 Enzyme and pathways 5 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).